Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

The Minister of Public Health Dr. Firass Abiad at COP28 in UAE

 
The Minister of Public Health (MoPH), Dr. Firass Abiad, will be participating in the COP28 held in UAE from November 30 to December 12, where leaders from around the world convene annually to address the dangerous human interference with the climate system. The Minister’s participation in COP28 UAE is particularly important as it would be the first COP with an explicit health focus. Dr. Abiad, the Minister of Public Health, Eng. Joyce Haddad, the Director of Preventive Healthcare at MoPH, Dr. Myriam Mrad, the Director of the Public Health Department at the University of Balamand and the Ministry Technical Collaborator will be representing the ministry of public health in the Lebanese national delegation.  

Minister Abiad will emphasize the imperative need to prioritize public health concerns in Lebanon within the broader discourse on climate change. Acknowledging the undeniable impact of environmental factors on human health, Dr. Abiad will commit to advocate for proactive measures and collaborative strategies to mitigate these effects in Lebanon.

The Minister will stress key initiatives aiming at safeguarding public health amidst environmental shifts, emphasizing the urgency of adaptation measures and the development of resilient healthcare systems. These initiatives align with the Lebanese Ministry of Public Health's commitment to promoting sustainable health practices and ensuring equitable access to healthcare for all citizens.

Additionally, Dr. Abiad will participate in high-level dialogues, fostering collaborations with global stakeholders and reaffirming Lebanon's dedication to the global fight against climate change, particularly in preserving public health.

It is worth noting that earlier this year, the MoPH endorsed COP26 proceedings in an official letter signed and dated March 26, 2023.  As part of this initiative, Lebanon committed to prioritizing the health needs of its population, while simultaneously addressing the environmental and sustainability challenges facing its healthcare facilities.

The MoPH remains steadfast in its commitment to integrating climate resilience into public health policies, aligning efforts with international agendas to safeguard the well-being of citizens and future generations.
    1
ATC Name B/G ↑ Ingredients Dosage Form Price
A10BH03 ONGLYZA B Saxagliptin HCl - 2.5mg 2.5mg Tablet 1,987,543 L.L
L01EX09 OFEV B Nintedanib - 100mg 100mg Capsule, soft 100,972,184 L.L
A10BH03 ONGLYZA B Saxagliptin HCl - 5mg 5mg Tablet 3,836,670 L.L
L01EX09 OFEV B Nintedanib - 150mg 150mg Capsule, soft 201,946,695 L.L
A10BJ06 OZEMPIC B Semaglutide - 0.25mg 0.25mg Injectable solution 10,927,526 L.L
A10BJ06 OZEMPIC B Semaglutide - 0.5mg 0.5mg Injectable solution 10,927,526 L.L
A10BJ06 OZEMPIC B Semaglutide - 1mg 1mg Injectable solution 10,927,526 L.L
G04CA02 OMNIC OCAS B Tamsulosin HCl - 0.4mg 0.4mg Tablet, film coated, prolonged release 866,778 L.L
C09CA08 OLMETEC B Olmesartan medoxomil - 10mg 10mg Tablet, film coated 710,893 L.L
C09CA08 OLMETEC B Olmesartan medoxomil - 20mg 20mg Tablet, film coated 888,280 L.L
A11CC03 ONE-ALPHA B Alfacalcidol - 2mcg/ml 2mcg/ml Injectable solution 2,218,684 L.L
A11CC03 ONE-ALPHA B Alfacalcidol - 2mcg/ml 2mcg/ml Injectable solution 4,219,665 L.L
C09CA08 OLMETEC B Olmesartan medoxomil - 40mg 40mg Tablet, film coated 920,532 L.L
A11CC03 ONE-ALPHA B Alfacalcidol - 1mcg 1mcg Capsule 3,735,882 L.L
A11CC03 ONE-ALPHA B Alfacalcidol - 0.25mcg 0.25mcg Capsule 1,138,235 L.L
A11CC03 ONE-ALPHA B Alfacalcidol - 0.5mcg 0.5mcg Capsule 943,377 L.L
A11CC03 ONE-ALPHA B Alfacalcidol - 0.5mcg 0.5mcg Capsule 942,034 L.L
A11CC03 ONE-ALPHA B Alfacalcidol - 2mcg/ml 2mcg/ml Drops solution 1,343,843 L.L
H01CC01 ORGALUTRAN B Ganirelix - 0.25mg/0.5ml 0.25mg/0.5ml Injectable solution 2,383,977 L.L
H01CC01 ORGALUTRAN B Ganirelix - 0.25mg/0.5ml 0.25mg/0.5ml Injectable solution 2,383,977 L.L
S02DA01 OTIPAX B Lidocaine HCl - 1g/100g, Phenazone - 4g/100g Drops 236,516 L.L
J01DD15 OMNICEF B Cefdinir - 125mg/5ml 125mg/5ml Powder for suspension 1,189,301 L.L
J01DD15 OMNICEF B Cefdinir - 125mg/5ml 125mg/5ml Powder for suspension 2,025,171 L.L
J01DD15 OMNICEF B Cefdinir - 125mg/5ml 125mg/5ml Powder for suspension 2,025,171 L.L
J01DD15 OMNICEF B Cefdinir - 125mg/5ml 125mg/5ml Powder for suspension 1,189,301 L.L
J01DD15 OMNICEF B Cefdinir - 300mg 300mg Capsule 2,238,842 L.L
J01DD15 OMNICEF 300 B Cefdinir - 300mg 300mg Capsule 2,238,842 L.L
J01DD15 OMNICEF B Cefdinir - 250mg/5ml 250mg/5ml Powder for suspension 3,670,034 L.L
M05BX OSSOPAN B Osseine-hydroxyapatite complex - 800mg 800mg Tablet, film coated 1,142,266 L.L
G03CA03 OESTRODOSE B Estradiol (17 bêta estradiol anhydre) - 0.06% 0.06% Gel 642,357 L.L
    1
Sitemap
© Copyrights reserved to Ministry of Public Health 2025